Purpose of review
Headache is not an uncommon complaint in children, and recognition of migraine is increasing in children and adolescents. Treatment options consist of abortive and preventive medications; however, when to start the preventive treatment is not clear in the pediatric population. This article reviews current guidelines and practices to provide a better clinical approach in the management of migraines in children and adolescents.
Currently, the only FDA-approved medical treatment option for preventive therapy in chronic migraine in adolescents is topiramate. However, the Childhood and Adolescent Migraine Prevention Study (CHAMP) did not endorse superiority of topiramate or amitriptyline over placebo.
At this time, there is no clear consensus on when to start preventive therapy in children and adolescents with migraines. The decision is multifactorial and should be initiated after a thorough discussion with the patient and caregiver(s) about related risks and benefits of treatment. Education regarding various modalities of treatment and ensuring compliance is essential to treatment success.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Headache Classification Committee of the International Headache Society. (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
Olesen J, Steiner T, Bousser MG, Diener HC, Dodick D, First MB, et al. Proposals for new standardized general diagnostic criteria for the secondary headaches. Cephalalgia. 2009;29(12):1331–6.
Arruda MA, Bigal ME. Migraine and migraine subtypes in preadolescent children: association with school performance. Neurology. 2012;79(18):1881–8.
Lipton RB, Manack A, Ricci JA, Chee E, Turkel CC, Winner P. Prevalence and burden of chronic migraine in adolescents: results of the chronic daily headache in adolescents study (C-dAS). Headache. 2011;51(5):693–706.
Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia. 2010;30(9):1065–72.
Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646–57.
Su M, Yu S. Chronic migraine: a process of dysmodulation and sensitization. Mol Pain. 2018;14:1744806918767697.
O’Brien HL, Kabbouche MA, Hershey AD. Treating pediatric migraine: an expert opinion. Expert Opin Pharmacother. 2012;13(7):959–66.
Winner P. Pediatric headache. Curr Opin Neurol. 2008;21(3):316–22.
Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl 1):S20–8.
Ware JE Jr. SF-36 health survey update. Spine (Phila Pa 1976). 2000;25(24):3130–9.
Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache. 2003;43(3):171–8.
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–9.
Kashikar-Zuck S, Zafar M, Barnett KA, Aylward BS, Strotman D, Slater SK, et al. Quality of life and emotional functioning in youth with chronic migraine and juvenile fibromyalgia. Clin J Pain. 2013;29(12):1066–72.
Connelly M, Rapoff MA. Assessing health-related quality of life in children with recurrent headache: reliability and validity of the PedsQLTM 4.0 in a pediatric headache sample. J Pediatr Psychol. 2006;31(7):698–702.
PedMIDAS Tool Cincinnati Children's Hospital Medical Center. Lipton and Stewart. Children's Hospital Medical Center, 2001
Headache Classification Committee of the International Headache S. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.
Powers SW, Mitchell MJ, Byars KC, Bentti AL, LeCates SL, Hershey AD. A pilot study of one-session biofeedback training in pediatric headache. Neurology. 2001;56(1):133.
Labbe EE. Treatment of childhood migraine with autogenic training and skin temperature biofeedback: a component analysis. Headache. 1995;35(1):10–3.
Werder DS, Sargent JD. A study of childhood headache using biofeedback as a treatment alternative. Headache. 1984;24(3):122–6.
FDA approves Topamax for migraine prevention in adolescents. J Pain Palliat Care Pharmacother. 2014;28(2):191.
Abstracts of the 47th Annual Congress of the Canadian Neurological Sciences Federation, June 5–8, 2012, Ottawa, Ontario, Canada. Can J Neurol Sci. 2012;39(3 Suppl 3):S1–54.
• Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med. 2017;376(2):115–24 Trial demonstrating no significant differences in reduction in headache frequency or headache-related disability in childhood and adolescent migraine with amitryptiline, topiramate, or placebo over a period of 24 weeks.
•• Fallah R, Fazelishoroki F, Sekhavat LA. Randomized clinical trial comparing the efficacy of melatonin and amitriptyline in migraine prophylaxis of children. Iran J Child Neurol. 2018;12(1):47–54 Recent randomized controlled trial comparing amitriptiline and melatonin for migraine prophylaxis and considered amitryptiline to be safer but associated with more adverse events.
Kacperski J, Hershey AD. Preventive drugs in childhood and adolescent migraine. Curr Pain Headache Rep. 2014;18(6):422.
Bonfert M, Straube A, Schroeder AS, Reilich P, Ebinger F, Heinen F. Primary headache in children and adolescents: update on pharmacotherapy of migraine and tension-type headache. Neuropediatrics. 2013;44(1):3–19.
Lipton RB, Silberstein SD, Saper JR, Bigal ME, Goadsby PJ. Why headache treatment fails. Neurology. 2003;60(7):1064–70.
Pakalnis A, Kring D. Zonisamide prophylaxis in refractory pediatric headache. Headache. 2006;46(5):804–7.
Fan PC, Kuo PH, Chang SH, Lee WT, Wu RM, Chiou LC. Plasma calcitonin gene-related peptide in diagnosing and predicting paediatric migraine. Cephalalgia. 2009;29(8):883–90.
Ahmed K, Oas KH, Mack KJ, Garza I. Experience with botulinum toxin type A in medically intractable pediatric chronic daily headache. Pediatr Neurol. 2010;43(5):316–9.
Cleophas TJ. Clinical trials with large numbers of variables: important advantages of canonical analysis. Am J Ther. 2016;23(3):e825–36.
Pandina GJ, Ness S, Polverejan E, Yuen E, Eerdekens M, Bilder RM, et al. Cognitive effects of topiramate in migraine patients aged 12 through 17 years. Pediatr Neurol. 2010;42(3):187–95.
Sakulchit T, Meckler GD, Goldman RD. Topiramate for pediatric migraine prevention. Can Fam Physician. 2017;63(7):529–31.
Conflict of Interest
Mushtaq Qureshi and Ferhad Bashir each declare no potential conflicts of interest. Gregory Esper reports other from NeuroOne, Inc., outside the submitted work.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Headache
About this article
Cite this article
Qureshi, M.H., Esper, G.J. & Bashir, F.F. When to Consider Prophylactic Antimigraine Therapy in Children with Migraine. Curr Treat Options Neurol 21, 15 (2019). https://doi.org/10.1007/s11940-019-0560-7
- Chronic migraines
- Prophylactic therapy
- Preventive therapy
- International Classification of Headache Disorders